This page shows the latest acalabrutinib news and features for those working in and with pharma, biotech and healthcare.
Following AZ’s success with Calquence (acalabrutinib) – a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor – TNB-486 will further diversify the company’s haematology pipeline that have the potential
The CALAVI phase 2 trials had been evaluating the efficacy and safety of Calquence (acalabrutinib) alongside best supportive care (BCS) in patients hospitalised with respiratory complications of COVID-19.
acalabrutinib) and its recently approved, Daiichi-partnered HER2-targeting ADC, Enhertu (trastuzumab deruxtecan).
AstraZeneca also received two positive opinions following the meeting, with a recommendation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia and a label extension of its PD-1 inhibitor Imfinzi (durvalumab)
Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in
Current treatment options for MCL include AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) and Johnson &Johnson/AbbVie’s BTK inhibitor Imbruvica (ibrutinib).
More from news
Approximately 1 fully matching, plus 30 partially matching documents found.
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...